Latest gross profit for CDNA: $160M, below the Healthcare sector average of $67B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
The latest gross profit for CDNA is $160M as of June 2026. That compares with $230M in the prior-year period — down 31.4% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Caredx's historical trend and sector peers before judging valuation or financial health.
Over the past year, CDNA's gross profit moved from $230M to $160M — a 31.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Caredx's operating scale or balance-sheet position.
Against Healthcare companies, CDNA currently prints $160M for gross profit, while the sector average sits near $67B. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at Caredx's growth, margins, and balance sheet.
A gross profit figure of $160M for CDNA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.
After noting CDNA's gross profit ($160M), review year-over-year change from $230M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.